Compare Quest Diagnostics Inc (DGX) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Quest Diagnostics Inc trades at $202.28 (market cap $22.80B), while Tencent Music Entertainment Group - ADR trades at $8.86 (market cap $14.62B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Tencent Music Entertainment Group - ADR pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| DGX | TME | |
|---|---|---|
Market Cap | $22.80B | $14.62B |
Sector | Health | Media |
52-Week High | $216.02 | $26.36 |
52-Week Low | $166.42 | $8.16 |
Enterprise Value | $28.82B | $11.39B |
Dividend Yield | 1.67% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
TME trades at $8.83, down 0.56% today, with neutral technical signals and mixed earnings performance. The company reported strong revenue growth to $32.90B in 2025 and maintains solid profitability with a 26.48% net margin. Recent news highlights strategic moves including the Ximalaya acquisition and SEND audio technology development. Analyst consensus is divided with a $14.00 price target suggesting significant upside from current levels.
The investment outlook balances attractive valuation metrics against competitive pressures. With a P/E of 10.57 and strong cash flow generation, TME offers value potential, though recent earnings misses and intensifying competition present near-term challenges. The stock appears positioned for recovery if execution improves and premium content initiatives gain traction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
